Clinical Trials on Prostatic Neoplasms

Total 107167 results

Nanjing University School of Medicine

Completed

The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach

Prostate Neoplasm | Prostatectomy

China
University Hospital, Ghent

Completed

Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT) (IMPRINT)

Prostatic Neoplasms | Prostate Cancer | Prostate Adenocarcinoma

Belgium
I.M. Sechenov First Moscow State Medical University

Completed

Prospective Comparison of the Four Biopsy Methods for Prostate Cancer Detection

Prostate Cancer | Prostate Adenocarcinoma

Russian Federation
George Washington University

Terminated

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

Prostate Adenocarcinoma

United States
I.M. Sechenov First Moscow State Medical University

Completed

Efficacy and Safety Assessment of IRE of Localized Prostate Cancer.

Prostate Cancer | Prostate Adenocarcinoma

Russian Federation
IRCCS Azienda Ospedaliero-Universitaria di Bologna
University of Bologna; Catholic University of the Sacred Heart; Michigan State... and other collaborators

Completed

Combined, Intensified and Modulated Adjuvant Therapy in Prostate Carcinoma

Prostate Cancer
Fundación Canaria de Investigación Sanitaria
Hospital Universitario de Canarias

Unknown

Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer (ENZART)

Prostate Carcinoma

Spain
University of Miami

Withdrawn

Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management (MGM)

Prostate Cancer | Prostate Adenocarcinoma

United States
Centocor, Inc.

Terminated

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Cancer, Prostate

United States, United Kingdom, Belgium, Germany, Spain, France, Austria
John Chang, MD

Unknown

An Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer (Clarity)

Prostate Adenocarcinoma

United States
Grupo de Investigación Clínica en Oncología Radioterapia

Recruiting

Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed With Prostate Carcinoma

Prostate Cancer

Spain
I.M. Sechenov First Moscow State Medical University

Recruiting

Efficacy and Safety Assessment of IRE of Localized Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma

Russian Federation
Sahlgrenska University Hospital, Sweden
Göteborg University

Recruiting

Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation? (PRODICA)

Prostate Cancer

Sweden
University of Miami
National Cancer Institute (NCI)

Completed

MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer (LEAD)

Prostate Cancer | Prostate Adenocarcinoma

United States
University Hospital, Brest

Completed

Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma (INTEVOPROSTATE)

Prostate Cancer

France
Northwestern University
Genzyme, a Sanofi Company

Withdrawn

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

PROSTATE CANCER

United States
Cambridge University Hospitals NHS Foundation Trust

Unknown

Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer (CAMPROBE)

Prostate Cancer | Prostate Biopsy

United Kingdom
David M. Schuster, MD

Terminated

FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer

Prostate Cancers

United States
University of Chicago

Active, not recruiting

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Prostate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Visually Enhanced Education About Prostate Cancer

Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Completed

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
John P. Fruehauf
Sanofi

Withdrawn

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate (2007-5904)

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate
National Cancer Institute (NCI)

Completed

Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer

Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
University Health Network, Toronto

Active, not recruiting

Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR (PSMA-DOCS)

Neoplasm, Prostate

Canada
University of Southern California
National Cancer Institute (NCI); National Institute for Biomedical Imaging...

Terminated

18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

Prostate Neoplasm

United States
Sandy Srinivas
Wyeth is now a wholly owned subsidiary of Pfizer; American Society of Clinical... and other collaborators

Terminated

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
University of California, Davis
Sanofi

Terminated

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma

United States
University of Oxford
Vaccitech (UK) Limited

Unknown

VAccination in Early and ADvanced Prostate caNCEr (ADVANCE)

Castration-resistant Prostate Cancer | Intermediate Risk Prostate Cancer

United Kingdom
University of Chicago
National Cancer Institute (NCI)

Completed

Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer | Stage IV Prostate Cancer

Singapore, United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Novartis Pharmaceuticals

Terminated

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Prostate Cancer | Castrate Resistant Prostate Cancer | Chemotherapy Naive Prostate Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery

Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Completed

Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery

Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
Hospital Universitari Vall d'Hebron Research Institute

Unknown

Comparison of Prostate Fusion Biopsies With Software and Cognitive

Prostate Cancer Detection | Fusion Prostate Biopsy

Spain
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Spanish Oncology Genito-Urinary Group
Pivotal S.L.

Active, not recruiting

Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer (QRT-SOGUG)

Prostate Cancer Stage III | Prostate Cancer Stage IV
NorthShore University HealthSystem
National Cancer Institute (NCI); Wake Forest University Health Sciences; Van... and other collaborators

Completed

Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a

Prostate Cancer | Prostate Cancer, Familial | Hereditary Prostate Cancer
University of Chicago
National Cancer Institute (NCI)

Completed

MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer

Stage II Prostate Carcinoma | Stage I Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Robotic Athermal Nerve-Sparing Radical Prostatectomy

Stage I Prostate Cancer | Stage IIA Prostate Cancer
Amgen

Completed

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Cancer | Prostate Cancer | Castrate-Resistant Prostate Cancer | Mestastatic Prostate Cancer
National Cancer Institute (NCI)

Terminated

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Prostate Neoplasms | Metastatic Castration Resistant Prostate Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Prostate Carcinoma Metastatic to the Bone

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Terminated

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Herlev and Gentofte Hospital
Bristol-Myers Squibb

Recruiting

Checkpoint Inhibitors and SBRT for mCRPC (CheckPRO)

Prostate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IV

Denmark
National Cancer Institute (NCI)

Completed

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States

Clinical Trials on Prostatic Neoplasms

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations